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Abstract
Heat shock protein 90 (HSP90) is a chaperone protein that stabilizes proteins involved in oncogenic and therapeu-
tic resistance pathways of epithelial cancers, including head and neck squamous cell carcinomas (HNSCCs). Here,
we characterized the molecular, cellular, and preclinical activity of HSP90 inhibitor SNX5422/2112 in HNSCC over-
expressing HSP90. SNX2112 inhibited proliferation, induced G2/M block, and enhanced cytotoxicity, chemosensi-
tivity, and radiosensitivity between 25 and 250 nM in vitro. SNX2112 showed combinatorial activity with paclitaxel
in wild-type (wt) TP53-deficient and cisplatin in mutant (mt) TP53 HNSCC lines. SNX2112 decreased expression
or phosphorylation of epidermal growth factor receptor (EGFR), c-MET, v-akt murine thymoma viral oncogene
homolog 1 (AKT), extracellular signal–regulated kinases (ERK) 1 and 2, inhibitor κB kinase, and signal transducer
and transcription factor 3 (STAT3), corresponding downstream nuclear factor κB, activator protein-1, and STAT3
reporter genes, and target oncogenes and angiogenic cytokines. Furthermore, SNX2112 enhanced re-expression
of TP53 and targets p21WAF1 and PUMA, while TP53 inhibitor Pifithrin or siRNA attenuated the antiproliferative
activity of SNX2112 in wtTP53 HNSCC in vitro. Prodrug SNX5422 similarly down-modulated key signal targets,
enhanced TP53 expression and apoptosis, and inhibited proliferation, angiogenesis, and tumorigenesis in a
wtTP53-deficient HNSCC xenograft model. Thus, HSP90 inhibitor SNX5422/2112 broadly modulates multiple
key nodes within the dysregulated signaling network, with corresponding effects upon the malignant phenotype.
Our data support investigation of SNX5422/2112 in combination with paclitaxel, cisplatin, and radiotherapy in
HNSCC with different TP53 status.
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Introduction
Biologic and small molecule inhibitors selectively targeting growth
factor receptors, signal kinases, and angiogenesis factor receptors have
undergone extensive preclinical and clinical studies in different cancers.
Relative to the success of targeted therapy against prevalent genetic
drivers in some hematologic malignancies (e.g., BCR/ABL), the clini-
cal activity of these agents in solid tumors has often been modest or
transient. Head and neck squamous cell carcinomas (HNSCCs) have
been the subject for clinical or preclinical studies of several targeted
agents against a few commonly activated or inactivated pathways, in-
cluding epidermal growth factor receptor (EGFR; cetuximab, gefitinib,
and erlotinib) [1–5], proteasome-dependent nuclear factor κB (NF-κB)
activation (bortezomib) [6,7], signal transducer and transcription fac-
tor 3 (STAT3; decoy oligonucleotide) [8], and disrupted tumor sup-
pressor TP53 (TP53 adenovirus) [9]. These agents have demonstrated
significant target-specific and preclinical activity but modest clinical
activity at achievable concentrations as monotherapy or in combination
with conventional therapies [1–9].
Studies of the signal and transcriptional mechanisms mediating
pathogenesis and resistance of HNSCC demonstrate frequent alter-
ation and complex cross talk among multiple pathways. This includes
co-activation of growth factor and cytokine receptors and their ligands
[EGFR, c-MET, tumor necrosis factor–α (TNF-α), interleukin-1
(IL-1), and IL-6], intermediate signal kinases [sarcoma Rous cellular
homolog (SRC), MAP or extracellular signal–regulated kinase (ERK)
kinase (MEK)–ERK1/2, phosphatidylinositol 3-kinase (PI3K)–v-akt
murine thymoma viral oncogene homolog 1 (AKT), and inhibitor
κB kinase (IKK)], and downstream transcription factors [activator
protein-1 (AP-1), NF-κB, and STAT3] that promote the malignant
phenotype [3,5–8,10–12]. Additionally, dysregulation of the key
tumor suppressor TP53 may result from transcriptional inactivation
or mutation in HNSCC subsets, which exhibit differences in response
to therapy [13–15]. Recent next-generation sequencing studies in
HNSCC support the prevalence of genetic alterations affecting multi-
ple growth factor receptors, PIK3CA and PTEN that regulate AKT,
components of the NF-κB pathway, and tumor suppressor TP53
[16,17]. Thus, it has become increasingly clear that the complex genetic
and epigenetic alterations in HNSCC and other solid cancers contrib-
ute to intrinsic or acquired resistance to targeted and standard cytotoxic
therapies [5,7,10–14]. Therefore, combinations or agents targeting
multiple components of the dysregulated network in HNSCC and
other solid cancers may have potential for broader activity [18–23].
Heat shock protein 90 (HSP90) is a molecular chaperone required
for the proper folding, stabilization, and function of many proteins,
including multiple overexpressed, mutated, or activated signal com-
ponents and transcription factors that serve as key nodes in the net-
work of pathways that promote cancer cell proliferation and survival
[24]. The ATP-dependent conformational state of HSP90 provides a
selective target for natural toxins (e.g., geldanomycins) and synthetic
inhibitors. Targeted inhibition of HSP90 leads to destabilization and
proteasomal degradation of a diverse array of its client proteins, con-
veying the potential to simultaneously modulate many signaling path-
ways that synergize to promote cancer progression and reduce the
development of resistance seen with more selective molecular targeted
agents [24–26].
Prior studies provide evidence that HSP90 activation by interferon
may contribute to EGF-mediated protection against the apoptotic
effects of interferon in HNSCC cells [27]. We recently showed that
wild-type (wt) EGFR is stabilized by HSP90 in HNSCC [28].
Enhanced activity of HSP90 inhibitor geldanomycin is observed in
HNSCC with increased HSP90 and RAS activity [29]. In addition
to the ability of HSP90 inhibitors to concurrently modulate multiple
key molecular targets, they can enhance standard cytotoxic modalities
such as chemotherapy and radiation therapy in cancers, including
HNSCC [25,26,28–31].
SNX5422 (also known as PF-04929113) is a water-soluble and
orally bioavailable prodrug of SNX2112 (PF-04928473), a potent
and highly selective small molecule inhibitor of HSP90 [32,33].
SNX2112 competitively binds to the N-terminal ATP pocket of
HSP90 family members (HSP90α, HSP90β, Grp94, and Trap-1)
and is highly potent against various cancers in vitro and in vivo [34–
37]. SNX5422 has recently completed phase I testing, which defined
tolerated dosages, and demonstrated prolonged disease stabilization
of >150 days with various schedules in 22% to 36% of subjects with
treatment-refractory cancers [38–40]. However, preclinical studies of
the molecular effects on the broadly dysregulated signal and transcrip-
tional network and therapeutic activity of 5422/SNX2112 have not
been reported in HNSCC. In the present study, we examined the
effects of SNX2112 and prodrug SNX5422 on the broad network of
dysregulated pathways and targets and therapeutic effects alone and in
combination with radiation and standard chemotherapies in preclinical
models of HNSCC.
Materials and Methods
Reagents
SNX5422 is a water-soluble and orally bioavailable prodrug of
SNX2112, a potent and highly selective small molecule inhibitor
of HSP90 [32,33]. Both were provided initially by Pfizer Inc and
subsequently by Esanex Inc. Cisplatin was obtained from APP
Pharmaceuticals (Lake Zurich, IL; #100351). Paclitaxel and TP53
inhibitor Pifithrin-α were from Sigma-Aldrich Inc (St Louis, MO;
#T7191; P4359).
Cell Lines and Cell Culture
Nine HNSCC cell lines (UMSCC) obtained from Dr T. E. Carey
(University of Michigan, Ann Arbor, MI) were recently characterized
by genotype and TP53 status [13,41,42]. Normal human epidermal
keratinocytes (HEKA) were obtained commercially (Invitrogen,
Carlsbad, CA). The characteristics and culture conditions for UMSCC
cell lines and HEKA cells were previously described [13] (see
Supplementary Methods).
Real-time Reverse Transcription–Polymerase Chain Reaction
Quantitative reverse transcription–polymerase chain reaction (RT-
PCR) was performed as described [13] (see Supplementary Methods).
Western Blot
Western blot was performed with antibodies indicated as described
[13] (see Supplementary Methods).
Tissue Array and Immunohistochemical Staining
A human tissue array with 20 HNSCC sections and 6 normal
mucosa sections [43] was used for staining for HSP90. Immuno-
histochemical staining of this tissue array and aHNSCCxenograftmodel
for HSP90 client proteins were performed as described [43,44] (see
Supplementary Methods).
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Cell Proliferation Assay
Cell proliferation was measured by standard 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium (MTT) or 2,3-bis-(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanalide (XTT) assay (Roche
Diagnostics, Indianapolis, IN [13]; see Supplementary Methods).
Cell Cycle Analysis
DNA cell cycle distribution analysis was performed by flow
cytometry as described [44] (see Supplementary Methods).
Annexin V Apoptosis Detection
UMSCC-1 cells were plated in 100-mm2 plates and treated the
following day with either 0.01% DMSO control or 50, 100, or
200 nM SNX2112. After drug treatment, cells were expanded
for 48 hours, collected at 70% to 80% confluence, and stained
with Annexin V–fluorescein isothiocyanate and propidium iodide
according to the manufacturer’s instructions (Sigma APOAF).
Transient siRNA Transfection
TP53 or pooled control siRNA was constructed by Thermo
Scientific (Lafayette, CO) and transfected in UMSCC-1 using
Lipofectamine RNAiMax according to the manufacturer’s instructions
(Invitrogen; see Supplementary Methods).
Clonogenic Radiation Survival Assay
Clonogenic assay was performed as described previously [45] and
in the Supplementary Methods.
Reporter Gene Assay
NF-κB, AP-1, STAT3, IL-8, and BCL-XL reporters and assays
were performed as described [22,23] (see Supplementary Methods).
Cytokine Analysis
Cell culture supernatant samples were centrifuged at 14,000 rpm
(10 minutes) to clear residual cellular debris. Individual bead kits
for IL-6, IL-8, and vascular endothelial growth factor (VEGF) were
purchased from Biosource (Invitrogen), and multiplex assays were
performed and read by Luminex, as described [46]. Each sample
was assayed in triplicate, and data were presented as means ± SD.
Tumor Xenograft Studies
Immunodeficient BALB/c severe combined-immunodeficiency
(SCID) mice were obtained from the Frederick Cancer Research and
Development Center, National Cancer Institute (Frederick, MD)
and housed in a specific pathogen-free animal facility. Animal care
and HSP90 inhibitor studies were performed under National Institutes
of Health (NIH) Animal Care and Use Committee–approved Protocol
1102-07. Tumor xenografts were established by injecting 5 × 106
UMSCC-1 cells subcutaneously into the left flank. Tumor-bearing
animals were randomized into experimental groups indicated (n =
10 each). PF-04929113 suspended in 0.5% carbomethylcellulose/
0.5% Tween 80 was administered through oral gavage. Tumor size
was measured three times weekly, and tumor volumes were calculated
as V (cm3) = (L × W 2)/2. Tumors were harvested for immuno-
histochemical analysis for selected HSP90 client proteins, proliferation
(Ki-67), apoptosis (terminal deoxynucleotidyl transferase nick end
labeling (TUNEL)], and microvessel density (CD31) [5,7], as
described in the Supplementary Methods.
Statistical Analysis
Significance of comparisons was determined where indicated by
Fisher’s Exact or Student’s t test where indicated.
Results
SNX2112 Inhibits Proliferation, Cell Cycle and Survival of
HNSCC Cells In Vitro
Detection of HSP90 has previously been reported in oral HNSCC
[47]. We showed that HSP90 immunostaining was detected or in-
creased in a majority (18 of 20) of HNSCC tumors from different
anatomic sites in a tissue microarray (Figure W1, A and B). Similarly,
increased expression of HSP90 mRNA and protein was detected by
RT-PCR and by Western blot in nine of nine HNSCC (UMSCC)
cell lines compared to human keratinocytes (Figure W1, C–E). The
panel included UMSCC lines derived from patients with aggressive
HNSCC (survival < 15 months), and exhibiting underexpression of
wtTP53 (UMSCC-1, -6, -9) or overexpression of mutant (mt)
TP53 (UMSCC-11A, -11B, -22B, -38, -46) [13,42]. Thus, the pat-
tern of increased expression of HSP90 in tumor tissue specimens and
cell lines supports the rationale for investigation of the molecular, cel-
lular, and antitumor activity of HSP90 inhibitors in HNSCC models.
Next, the effect of selective HSP90 ATPase inhibitor SNX2112
[32,33] on proliferation of a subpanel of six of these UMSCC lines
was examined over 5 days by MTT assay (Figures 1A and W2).
SNX2112 inhibited cell density in a dose-dependent manner with
an inhibitory concentration 50% (IC50) range of 22 to 68 nM
(Figure 1A), demonstrating activity over a similar range in six distinct
UMSCC cell lines, without apparent relationship to HSP90 over-
expression (Figure W1) or TP53 genotype. Cell cycle and cytotoxic
effects of SNX2112 HSP90 inhibition were further examined by pro-
pidium iodide DNA flow cytofluorometric analysis and compared in
UMSCC-1 (wtTP53) and UMSCC-38 (mtTP53) cells (Figures 1B,
left panels, and W3). In wtTP53 UMSCC-1, SNX2112 at 50 nM
inhibited cell cycle, with increased accumulation in the G2/M phase
compared to untreated controls, 49% versus 23% at 48 hours
(Figure 1B, left panels) and 29% versus 17% at 72 hours (not shown).
There was also increased accumulation of fragmented sub-G0 DNA
(15%) compared to untreated controls (1%) at 48 hours (Figure 1B,
left panels) and 28% versus 2%, respectively, at 72 hours (not shown),
indicative of cell death. We performed Annexin V–fluorescein iso-
thiocyanate staining, providing evidence for increased apoptosis with
concentration (Figure 1B, right panels). Treatment of mtTP53
UMSCC-38 cells with 50 nM SNX2112 for 48 hours showed a similar
accumulation in the G2/M phase (48% vs 18%) but a lesser increase in
sub-G0 cells (6% vs 4%; Figure W3), consistent with the higher IC50
observed in Figure 1A. This trend was also seen after 72 hours of drug
treatment. The results suggested that despite similarities in G2/M cell
cycle block, the UMSCC-1 line deficient for wt TP53 and lower IC50
was more sensitive to apoptosis than the UMSCC-38 line with
mtTP53 and highest IC50. To examine the potential contribution of
wtTP53 in UMSCC-1 to antiproliferative effects of SNX2112, cells
were pretreated with TP53 inhibitor Pifithrin or TP53 siRNA before
SNX2112. Pifithrin and TP53 siRNA attenuated the antiproliferative
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effects and doubled the IC50 of SNX2112, supporting a role for
wtTP53 in effects of the HSP90 inhibitor in UMSCC-1 (Figure 1,
C and D).
SNX2112 Inhibits Cell Survival and Sensitizes HNSCC
Tumor Cells to γ-Radiation and Chemotherapy In Vitro
The observed effects of SNX2112 on sub-G0 cell death as well as
G2/M phases of the cell cycle sensitive to radiation, led us to further
investigate the effects of HSP90 inhibition on clonogenic cell survival
without and with radiation in UMSCC-1 in vitro. While MTT assay
indicated the IC50 for proliferation of UMSCC-1 was ∼30 nM, pilot
clonogenic survival assays with SNX2112 alone indicated that inhib-
itory concentrations for clonogenic cell survival were in a higher
range, between 100 nM (90% survival) and 500 nM (59% survival),
consistent with the relatively modest effects of the lower concentra-
tion of HSP90 inhibitor on cell survival seen by DNA flow cyto-
metry. Pre-exposure of cells to an intermediate concentration of
SNX2112 of 250 nM alone for 24 hours had a modest effect on
clonogenic tumor cell survival [surviving fraction of 73.5 ± 9.5%
(SD)], but this concentration significantly enhanced radiosensitivity,
with a dose modification factor (DMF) of 1.55 ± 0.11 (fold ± SD) at
10% survival (Figure 2A). Post-radiation treatment for 24 hours with
250 nM SNX2112 showed no enhancement of radiosensitivity (data
not shown).
We next examined the combinatorial effects of HSP90 inhibitor
with chemotherapeutic agents paclitaxel and cisplatin, which are
active in HNSCC, using two wtTP53 and two mtTP53 UMSCC
lines, at subtherapeutic inhibitory concentrations of SNX2112 or
chemotherapy drugs alone (Figure 2B). Interestingly, HSP90 in-
hibitor and paclitaxel showed combined activity in UMSCC-1 and
UMSCC-9 deficient for wtTP53, while combined activity with
cisplatin was observed in cell lines UMSCC-38 and UMSCC-46
expressing mtTP53. Conversely, sensitization to paclitaxel was not ob-
served in UMSCC-38 and UMSCC-46, or to cisplatin in UMSCC-1
or UMSCC-9 (data not shown), indicating that response to these
chemotherapy drugs in combination with HSP90 inhibitor was
associated with differences in TP53 status. Together, the above results
indicate that HSP90 inhibition has antiproliferative, cytotoxic, radia-
tion, and chemosensitizing activity, associated with TP53 genotype
in HNSCC lines in vitro. The SNX2112 concentrations of 22 to
68 nM having antiproliferative and chemosensitizing activity in
MTT assay, and 250 nM having radiosensitizing activity in clonogenic
assay, are clinically relevant, as they are within the range of concen-
tration maxima achievable (Cmax∼77-4098 nM) in patient serum
between dosages of 4 and 133 mg/m2, where disease stabilization
was observed in a recent NIH phase I clinical trial [38].
SNX2112 Inhibits Oncogenic Signaling Pathways and Induces
TP53 Protein and Target Gene Expression In Vitro
Western blot analysis of UMSCC-1 (deficient wtTP53) and
UMSCC-38 (mtTP53) cells treated over a range of inhibitory con-
centrations of SNX2112 revealed modulation of expression of several
important signaling molecules, transcription factors, and target genes
previously shown to be altered and promote the malignant phenotype
of HNSCC (Figures 3 and W4). Lower SNX2112 concentrations of
25 to 50 nM tested initially inhibited expression of hepatocyte growth
factor (HGF) receptor c-MET and phosphorylation of downstream
kinases AKT (Ser473 and Thr308) and ERK1/2 in both cell lines
(Figures 3A and W4, left panels). AKT phosphorylation exhibited
an oscillatory pattern of inhibition and reactivation between 24 and
72 hours in both lines, similar to that observed with PI3K-mTOR
inhibitors, as reported with loss of mTOR-mediated negative feedback
inhibition of PI3K [48]. Higher concentrations of 100 to 200 nM
for 24 to 72 hours were required for decrease of growth factor receptor
EGFR, prosurvival pathway components phospho-STAT3 and total
STAT3, IKKα and β, phospho–NF-κB/p65, NF-κB– and STAT3–
co-regulated prosurvival protein BCL-XL, and cleavage of cell death
marker poly (ADP-ribose) polymerase (c-PARP Figures 3A and
W4, right panels). Further examination of the SNX2112-sensitive
UMSCC-1 line deficient for wtTP53 revealed that the inhibitor also
upmodulated expression of TP53 and its target proteins, p21WAF1
and isoform PUMAα, in a time- and dose-dependent manner over
72 hours (Figure 3A, left panels). SNX2112 also enhanced expression
of p21WAF1 in UMSCC-38 (Figure W4), previously shown to overex-
press a missense mtTP53 and TAp73, which can also potentially activate
TP53 target genes [13].
We further assessed the functional effects of HSP90 inhibitor on
reporter activity for downstream proto-oncogenic transcription
factors and expression of several of their target genes and proteins
implicated in phenotype and resistance of HNSCC. Overall,
SNX2112 significantly inhibited NF-κB, AP-1, and STAT3-specific
reporter genes (Figure 3B) over a concentration range within which
inhibition of known upstream signal molecules was observed above.
However, weaker inhibition of STAT3 reporter activity was detected
Figure 1. Effect of SNX2112 on cell density, cell cycle, survival, and dependence on TP53 in vitro. (A) Left panel: Cellular density by
MTT-based colorimetric assay for UMSCC-1 cells after 3 days of drug treatment. Right panel: IC50 values for six UMSCC cell lines for
day 3 of drug treatment from cellular density MTT-based colorimetric assays. Cell lines treated with five drug concentrations indicate
dose-dependent inhibition of cellular proliferation with IC50 values between 22 nM for UMSCC-46 and 68 nM for UMSCC-38. (B) Left panel:
Flow cytometric cell cycle analysis using propidium iodide DNA staining of UMSCC-1 cells following 48 hours of treatment with 50 nM
SNX2112. Drug treatment led to accumulation of cells in the sub-G0 and G2/M phases compared to controls. Right panel: Apoptosis marker
Annexin V+/PI− staining after 48 hours of treatment with 50, 100, or 200 nM SNX2112 compared to DMSO control. (C) wtTP53 UMSCC-1
was pretreated for 5 hours with 10 μM Pifithrin-α, a selective inhibitor of TP53, or DMSO control and subsequently exposed to 50 nM
SNX2112 or DMSO control for 2 days. Cell density was measured through XTT assay 2 days after drug exposure. Pifithrin-α treatment
alone did not inhibit growth of UMSCC-1. Combination treatment of UMSCC-1 with Pifithrin-α and SNX2112 attenuates the inhibitory
effects of SNX2112 alone. Statistical analysis was performed using a Student’s t test with *P ≤ .01 and ***P ≤ .001. (D) wtTP53
UMSCC-1 cells were simultaneously transfected with p53-targeting siRNA or nontargeting control siRNA and, the following day, were
treated with a range of SNX2112 doses from 1 nM to 5 μM. Two days after drug exposure, IC50 of each condition was determined using
a nonlinear regression model.
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beginning at lower concentrations than required for inhibition of
STAT3 phosphorylation and incompletely inhibited at higher con-
centrations where minimal STAT3 phosphorylation was detected
at 48 hours in Figure 3A, suggesting the drug may have more com-
plex effects involving other determinants of STAT activation or
STAT family members. IL-8 cytokine and BCL-XL prosurvival gene
reporters sharing enhancer elements for two or three of these transcrip-
tion factors were also inhibited (Figure 3B). Furthermore, SNX2112
Figure 2. Effect of SNX2112 in combination with radiotherapy or chemotherapy. (A) Clonogenic survival curves for UMSCC-1 cells treated
with radiation alone (open circles) or 250 nM SNX2112 for 24 hours followed by radiation (closed circles). The DMF was 1.55 ± 0.11,
revealing a radiosensitizing drug effect. (B) Two HNSCCs with wtTP53 (UMSCC-1 and UMSCC-9) and two with mtTP53 genotype
(UMSCC-38 and UMSCC-46) were incubated with paclitaxel, cisplatin, and SNX2112 alone or in combination at subinhibitory concentra-
tions for the drugs for the cell lines. These were given as follows: 25 nM SNX2112 and 3 nM paclitaxel for UMSCC-1; 37.5 nM SNX2112
and 3 nM paclitaxel for UMSCC-9; 75 nM SNX2112 and 10 μM cisplatin for UMSCC-38, and 37.5 nM SNX2112 and 2.5 μM cisplatin for
UMSCC-46. SNX2112 showed combinatorial activity with paclitaxel in HNSCC with wtTP53 (UMSCC-1 and UMSCC-9) and with cisplatin in
lines with mtTP53 (UMSCC-38 and UMSCC-46) by MTT assay.
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Figure 3. Effects of SNX2112 on oncogenic HSP90 clients, TP53 and target protein expression, prosurvival transcription factors, and
proinflammatory and angiogenic cytokines in vitro. (A) Western blot analysis of whole-cell lysates from UMSCC-1 cells treated with 25 or
50 nM SNX2112 (left panel) or 100 or 200 nM SNX2112 (right panel) for 24, 48, and 72 hours. Protein density relative to 0-hour untreated
control and actin loading control is quantified above each individual protein band. (B) Reporter gene activity of plasmid-transfected tumor
cells in the presence of SNX2112 at 24 and 48 hours. Reporter plasmids include NF-κB, AP-1, STAT3, IL-8, and BCL-XL. *P < .05 indicates
statistical difference between control and SNX2112-treated groups (Student’s t test). (C) Luminex multiplex assay measuring tumor cell
production of IL-6, IL-8, and VEGF cytokines in the presence of increasing concentrations of SNX2112 at 24 and 48 hours. *P< .05 indicates
statistically significant difference compared to controls.
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inhibited expression of NF-κB– and AP-1–co-regulated IL-6, IL-8,
and VEGF proteins implicated in tumor angiogenesis [49–52] in
culture supernatants (Figure 3C ). Consistent with inhibition of
ERK and AP-1, AP-1 target VEGF was decreased by treatment with
SNX2112 (50 nM). Significant inhibition of IKK–NF-κB and
dependent gene IL-8 required intermediate drug concentrations
≥100 nM. Inhibition of STAT3 inducer IL-6, STAT3, and co-
regulated target BCL-XL required drug concentrations ≃200 nM.
The cumulative effects of increasing concentrations of SNX2112
on key components of these signal transduction pathways and tar-
gets are consistent with the ranges in which significant inhibition of cell
density in MTT assay (25-50 nM), angiogenesis factor expression
(>100 nM), and decreased radiation clonogenic cell survival (250 nM)
were observed.
SNX5422 Inhibits Tumorigenesis and Modulates Markers
of Proliferation, Apoptosis, and Angiogenesis In Vivo
We next examined the effects of the prodrug SNX5422 on tumor
growth, survival, and angiogenesis and a panel of these molecular
markers in wtTP53-deficient UMSCC-1 xenografts in vivo. After
tumors were established, SNX5422 was administered for 21 days on
two different dose schedules, 20 mg/kg daily (Monday to Friday) or
50 mg/kg every other day (Monday, Wednesday, and Friday). The
concentration average for free drug for 50 mg/kg every other day used
in mice is approximately equivalent to that achieved with 100 mg/m2
in human phase I studies ( J. Kan, N. Brega, and Pfizer, unpublished
pharmacokinetic data). Biologic outcomes, including tumor growth,
survival, and body weight, were measured and compared to placebo-
treated controls (Figure 4). The rate of tumor growth was significantly
and similarly inhibited in both 20 mg/kg (Monday to Friday) and
50 mg/kg (Monday, Wednesday, and Friday) treatment groups com-
pared to controls while on treatment for 3 weeks. Once treatment was
discontinued, both experimental groups demonstrated tumor growth
at a rate similar to that seen in controls (Figure 4A). Suppression of
tumor growth corresponded with a survival benefit for treated animals
versus controls of ∼2 weeks (Figure 4B). Toward the end of 3 weeks
of treatment with SNX5422, 50 mg/kg (Monday, Wednesday, and
Friday), gastrointestinal and systemic toxicities (diarrhea, piloerection,
and lethargy) were observed and associated with death in 2 of 10 ani-
mals. The toxicities resolved in the remaining animals once the drug
was discontinued. No systemic toxicity was apparent in the lower
dose treatment group. A second controlled study of treatment with
the lower dose of SNX5422, 20 mg/kg (5 days per week), for up to
6.5 weeks revealed sustained tumor stabilization while on treatment,
an overall survival benefit exceeding 2 weeks, and minimal toxicity
(Figure W5). In both studies, fluctuation in body weight was seen
during weekdays of treatment in both vehicle and drug-treated mice,
likely due to hyperosmotic or other effects of the methylcellulose/
Tween 80 vehicle used for drug delivery.
Effects of HSP90 Inhibition on Target Biomarkers In Vivo
Tumor specimens from extra control and mice treated with both
concentrations/schedules during the 3-week in vivo study were har-
vested on days 16, 21, and 25 after tumor inoculation (days 9, 14,
and 18 of treatment) for immunohistochemical comparison of se-
lected HSP90 clients characterized above and markers of proliferation
(Ki-67), apoptosis (TUNEL), and angiogenesis (CD31). Maximal
effects on individual tumor markers were observed in specimens by
day 16 or day 21, and representative sections demonstrating treatment-
induced modulation are shown in Figure 5A. HNSCC tumors from
SNX5422-treated mice showed decreased immunostaining for pro-
growth and prosurvival signal molecules c-MET, SRC, p-AKT, and
p-ERK1/2 and transcription factor p-STAT3, while that for pro-
apoptotic transcription factor TP53 and target PUMA was increased.
Corresponding to the well-established cellular functions of these path-
ways, SNX5422 inhibited proliferation, as indicated by reduced Ki-67,
and induced apoptosis, as evidenced by an increase in tumor apoptotic
index, measured by TUNEL staining (Figure 5, A and B). Consistent
with the inhibition of tumor angiogenic cytokine production observed
in vitro (Figure 4C ), tumors treated with SNX5422 also showed an
overall reduction in CD31+ vessel density (Figure 5, A and B). Together,
these results provide evidence that SNX5422 treatment suppresses
tumor growth in vivo by modulating the expression of known clients
Figure 4. Effect of SNX5422 on tumor growth in vivo. SCID mice
were inoculated on day 0 with UMSCC-1 cells, then randomized
and treated on day 7. Mice received 20 mg/kg SNX5422 on a
Monday to Friday daily schedule or received 50 mg/kg SNX5422
on a Monday, Wednesday, Friday schedule. Drug dissolved in
methylcellulose solution or methylcellulose alone as control was
given through oral gavage. Mice were treated for a total of 3 weeks
(indicated by bars along the x-axis). (A) Tumor growth, (B) survival,
and (C) body weight in control and treated animals. *P < .05 indi-
cates statistical difference between control and 20 mg/kg treated
group (Student’s t test); +P < .05 indicates statistical difference
between control and 50 mg/kg treated group (Student’s t test).
Arrows above tumor growth curves (A) indicate days 16, 21, and
25 when tumors were harvested from all three experimental groups
for immunohistochemical analysis.
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Figure 5. SNX5422 effects onmolecular markers in vivo. Tumors were harvested from control and treated mice on days 16, 21, and 25, and
frozen sections were prepared for immunohistochemical analysis of tumor marker expression. Maximal effects of drug-inducedmodulation
of individual tumor marker expression were observed on day 16 or day 21, and representative sections are shown. (A) Immunostaining
patterns of c-MET, p-AKT, p-ERK1/2, SRC, and p-STAT3 (top panel) as well as CD31, Ki-67, TUNEL, p53, and PUMA (bottom panel) were
compared in control and treated groups (original magnification, ×400). (B) TUNEL assay was performed to quantify apoptotic cells in treated
tumor specimens by counting the positive cells in three high power fields (HPFs; ×400, left panel); quantitation of CD31-positive vessel
density in tumors (right panel). *P < .05 indicates statistical difference between treated groups and controls (Student’s t test).
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of HSP90 and their targets mediating proliferation, survival, and angio-
genesis in HNSCC.
Discussion
Here, we show that HSP90 inhibitor SNX5422/2112 inhibits prolif-
eration of a panel of six UMSCC lines (Figure 1) that exhibit increased
HSP90 (Figure W1), along with dysregulation of a network of pro-
oncogenic signal components and tumor suppressor TP53 found in
HNSCC (Figures 3, 5, and 6). HSP90 inhibition increased G2/M
cell cycle blockade, sub-G0 DNA, and apoptotic marker Annexin
(Figures 1B and W3) and showed combined activity with radiation
or cisplatin or paclitaxel chemotherapies active in HNSCC (Figure 2).
HSP90 inhibition broadly suppressed the dysregulated network of pro-
oncogenic signal components and transcription factors in vitro and
in vivo (Figures 3, W4, 5, and 6) and prolonged progression-free
survival in an HNSCC xenograft model in vivo (Figures 4 and
W5). Inhibition of prosurvival pathway components EGFR, NF-κB,
STAT3, and their antiapoptotic target BCL-XL was associated with
PARP cleavage and decreased clonogenic survival in vitro (Figures 2A,
3A, and W4A). TP53 inhibition by Pifithrin or siRNA partially at-
tenuated the inhibitory effects of SNX2112 observed in UMSCC-1
with wtTP53 (Figure 1, C and D), supporting a role for TP53. Fur-
ther, SNX2112 induced sub-G0 DNA and TUNEL activity was asso-
ciated with increased TP53 and target proapoptotic protein PUMA in
UMSCC-1 in vitro and in vivo (Figures 3A and 5). Interestingly, sen-
sitivity to HSP90 inhibitor in combination with chemotherapy agent
cisplatin or paclitaxel (Figure 2B) also appeared to differ with TP53
status. SNX2112 enhanced paclitaxel sensitivity of UMSCC-1 and
UMSCC-9 with wtTP53 but not UMSCC-38 and UMSCC-46 with
mtTP53 (Figure 2B; not shown). Conversely, SNX2112 showed
enhanced activity with cisplatin in UMSCC-38 and UMSCC-46, with
mtTP53. We observed potent suppression of tumorigenesis in an
HNSCC xenograft model with inhibition of EGFR, c-MET, p-AKT,
p-ERK, SRC, and p-STAT3 and, conversely, the re-expression of pro-
apoptotic TP53 and PUMA (Figures 4 and 5). Corresponding reduc-
tions in proliferation (Ki-67) and angiogenesis (CD31) and increased
apoptosis by TUNEL assay were observed. Together, these preclinical
studies support further investigation of SNX5422/2112 and these
molecular targets, which are implicated in sensitivity to HSP90 inhibitor
alone or in combination with cytotoxic chemotherapy and radiotherapy
in patients with HNSCC.
We have previously shown that HNSCC tumors and UMSCC lines
exhibit concurrent activation or disruption of several signaling path-
ways, which contain multiple HSP90 clients important in cancer
Figure 6. Model of the signal transduction and transcription factor network in HNSCC. Key components of the signal transduction and
transcription factors implicated in cell proliferation, survival, and malignant phenotype of HNSCC are shown. Labels in red depict HSP90
clients forming key nodes that are inhibited by SNX5422/2112 (see Discussion section for details). Abbreviations: HGF/c-MET-R, hepatocyte
growth factor/c-MET receptor; EGF/EGFR, epidermal growth factor/receptor; TNF-α/TNFR, tumor necrosis factor–α/receptor; IL-1α/IL-1R,
interleukin-1α/receptor; IL-6/IL-6R, interleukin-6/receptor; MEK, ERK kinase; ERK, extracellular signal–regulated kinase; AP-1, activator pro-
tein-1; PI3K, phosphatidylinositol 3-kinase; AKT, v-akt murine thymoma viral oncogene homolog 1; p53, protein 53 kDa; TAK, transforming
growth factor β–activated kinase; IKK, inhibitor κB kinase; IκB-α, inhibitor κB B-alpha; NF-κB p65/p50, nuclear factor κB 65/50 kDa; SRC,
sarcoma Rous cellular homolog; JAK, Janus activated kinase; STAT3, signal transducer and transcription factor 3.
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(Figure 6). These include EGFR, c-MET, and TNF receptors and their
ligands that contribute to cross-activation of the MEK–ERK–AP-1 and
PI3K-AKT axes [22,49–52], TNF and IL-1 that co-activate the IKK–
NF-κB axis [52,53], and EGF, IL-6, or both that can variably induce
MEK- or Janus activated kinase–mediated STAT3 pathway activation
[50]. Conversely, we showed that tumor suppressor TP53 is inactivated
or mutated in subsets of HNSCC [13] and inversely co-modulated
with these other pathways, suggesting a potential linkage [22]. The
altered signaling pathways in this network have been individually
shown to contribute to the promotion of cell proliferation, survival,
expression of inflammatory and angiogenesis factors, and therapeutic
resistance that comprise important hallmarks of cancer [13,22,44–53].
However, intrinsic and acquired resistance to therapies targeting indi-
vidual components, such as EGFR, proteasome-dependent activation
of NF-κB, or mutated or inactivated TP53, has been attributed to lim-
ited modulation or compensatory activation of other signal molecules
and pathways in experimental studies and clinical trials [5,7,12]. The
concurrent modulation of multiple signaling pathways by HSP90
inhibition uniquely differentiated its effects from previous targeted
agents. Specifically, EGFR inhibitors often failed to simultaneously
block AKT, ERK, and SRC kinases and downstream transcription fac-
tors NF-κB, AP-1, and STAT3 [5,12]. While proteasome inhibitor
bortezomib effectively inhibited the activation of NF-κB p65, it did
not inhibit other signaling molecules, such as noncanonical NF-κBs,
p-ERK1/2, or STAT3 [7]. MET inhibition also affected downstream
signal inhibition in only a subset of HNSCC [11]. In addition to the
ability of HSP90 inhibitors to concurrently modulate multiple key
molecular targets, they can enhance standard cytotoxic modalities such
as chemotherapy and radiation therapy in HNSCC (Figure 2).
In our study, we observed differential activity of SNX2112 on cell
growth arrest, apoptosis, combination therapy, and HSP90 client
expression based on dose and duration of exposure to drug and the
cell line examined. At lower concentrations (25-50 nM SNX2112),
inhibition of c-MET, p-AKT, and p-ERK and induction of TP53
and p21 were associated with decreased cell proliferation in both
UMSCC-1 and UMSCC-38 (Figures 1, 3, and W2–W4). These
findings are consistent with our previous demonstration that HGF–
c-MET contributes to activation of p-ERK and p-AKT and prolifera-
tion, which can be partially blocked by MEK or PI3K inhibition [49].
In the prior study, we further showed that HGF–c-MET induced
MEK-ERK and PI3K-AKT activation contributes to co-expression of
angiogenesis factors IL-8 and VEGF, which were also inhibited at lower
concentrations of SNX2112 in the present study (Figure 3, B and C).
However, oscillation and re-phosphorylation of ERK and AKT were
observed at lower concentrations over the time course between 48
and 72 hours. Of potential relevance, higher concentrations of
SNX2112 (≥200 nM) were required for inhibition of EGFR, which
can co-activate ERK, AKT, as well as STAT3, and for inhibition of
IKK–NF-κB pathway components. Similarly, high concentrations
of SNX2112 were required for inhibition of STAT3 and NF-κB–
regulated antiapoptotic gene BCL-XL, cleavage of apoptotic marker
PARP (Figures 3 and W4), and decreased clonogenic cell survival
(Figure 2A). wtEGFR was recently shown to be a client but a rela-
tively resistant target for HSP90 inhibitors [28]. Both STAT3 and
IKK proteins appeared to be increased at 100 nM and required 200 nM
SNX2112 for inhibition. Together, these observations suggest that in-
complete HSP90 or target inhibition may enhance phosphorylation
of ERK and AKT and expression of STAT3 and IKKs at concentra-
tions below those required for destabilization and degradation of these
proteins. Determination of the mechanism(s) for the compensatory
enhanced expression and activation of these pathways that are critical
to HNSCC cell survival could potentially lead to other combinations
with HSP90 inhibitors that would enhance inhibition and cytotoxicity.
A potentially important finding of this study is that TP53, PUMA,
and p21 were upmodulated by HSP90 inhibition in HNSCC with
wtTP53 (Figure 3A). AKT has been reported to be a key node inhib-
iting TP53 gene transactivation by phosphorylation and modulation of
cofactors, CBP/p300 and MDM2 [54–57]. Recently, another role of
HSP90 inhibitors in releasing HSP90-RNA polymerase complexes
paused at promoters has been implicated in upregulating repressed
genes including TP53 [58]. We also observed combined effects of
SNX2112 with cytotoxic chemotherapy agents paclitaxel and cisplatin
that were related to TP53 status. Paclitaxel has been reported to induce
p21, inhibit microtubule-dependent cell division and G2/M block, and
induce cell death enhanced by TP53 [59], potentially explaining the
combined effect observed in HNSCC with wtTP53. Cisplatin cyto-
toxicity can be mediated by degradation of TP53 family antagonist
ΔNp63 and activation of TAp73, which we recently showed are over-
expressed with mtTP53 in the subset of UMSCC that were sensitive to
combined cisplatin and SNX2112 [60,61]. Confirmation of these com-
bined effects in wider subsets could potentially help in enhancing the
limited cytotoxicity observed with these chemotherapeutics and in
selecting optimal combinations for patient therapy.
HSP90 inhibition potently suppressed tumorigenesis in a preclinical
HNSCC xenograft model in concert with potent inhibition of pro-
oncogenic signaling and induction of expression of proapoptotic
TP53. Supporting the clinical potential of HSP90 inhibition and
SNX5422, a recent NIH phase I study found SNX5422 administered
twice weekly was well tolerated with mild adverse events [38]. Fifteen of
32 patients (47%) achieved disease stabilization, with 22% exceeding
150 days after progression of a variety of treatment refractory solid
tumors and lymphomas. SNX5422 administered every other day at
doses ranging from 9 to 100 mg/m2 was also tolerated, with one
complete response, one partial response, and seven patients with stable
disease for >150 days [35]. Diarrhea was dose limiting, as found in our
murine study. However, subjects receiving 50 to 89 mg/m2 SNX5422
daily exhibited dose-limiting ocular toxicity, and thus, every other day
schedules have been recommended for future studies [39,40]. Impor-
tantly, the molecular and anticancer effects observed in HNSCC in the
25 to 250 nM range in vitro and concentration average for free drug for
50 mg/kg every other day used in mice in our preclinical studies were
within the range attained in serum in patients who demonstrated
disease-stabilizing activity and acceptable toxicity.
Regarding clinical potential of HSP90 inhibitors in squamous cell
carcinoma, we previously observed prolonged stabilization of pulmo-
nary metastasis for 8 months in a heavily pretreated patient in an NIH
phase I study using geldanomycin 17-DMAG [62]. Geldanomycin
derivative IPI-504 in combination with docetaxel was reported to
induce partial responses or prolonged stable disease, particularly in
patients with squamous cell carcinomas of the lung [63]. Together,
these clinical data and our preclinical data support further investiga-
tion of SNX5422 and HSP90 inhibitors in combination with chemo-
therapy or radiation therapy in HNSCC.
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Figure W1. HSP90 is overexpressed in human HNSCC and in UMSCC cell lines. (A) Representative tissue sections of immunohisto-
chemical staining patterns for total HSP90 protein expression in normal human oral squamous epithelium and in three representative
HNSCC tumor specimens exhibiting low (+1), moderate (+2), and high (+3) staining intensity patterns. Original magnification, ×200.
(B) Comparison of staining intensity score distributions between normal and tumor specimens shows that distribution of higher HSP90
staining intensity is greater in tumors compared to normal specimens, Fisher’s exact test (P = .01). (C) HSP90 mRNA expression in
UMSCC cell lines. Total RNA was isolated from HEKA cells (normal proliferating human epithelial keratinocytes) and nine UMSCC
cell lines. HSP90 mRNA expression was determined by real-time RT-PCR. *P < .05 denotes statistical significance by Student’s t test.
(D, E) Western blot and densitometry analysis of HSP90 protein expression in UMSCC cell lines compared to HEKA controls.
Figure W2. In vitro effect of SNX2112 on cellular proliferation in UMSCC-9, -11B, -22B, and -38 cell lines. Cellular proliferation was
measured by MTT-based colorimetric assay in UMSCC-9, -11B, -22B, and -38 cells after 1, 3, and 5 days of drug treatment. Cell lines
were treated with five drug doses with increasing concentrations, leading to progressive inhibition of cellular proliferation.
Figure W3. SNX2112 induces cell cycle arrest in UMSCC-38 cells in vitro. Flow cytometric cell cycle analysis was performed using
propidium iodide DNA staining of UMSCC-38 cells following 48 and 72 hours of treatment with 50 nM SNX2112. Drug treatment for
both 48 and 72 hours decreased the number of cells in the G0/G1 and S phases and induced a substantial accumulation of cells in the
G2/M phase, as well as a more modest increase in the number of apoptotic cells in the sub-G0 phase.
Figure W4. Effects of SNX2112 on oncogenic HSP90 clients or dependent proteins in UMSCC-38. Western blot analysis of whole-cell
lysates from mtTP53 UMSCC-38 cell line treated with 25 or 50 nM SNX2112 (left panel) or 100 or 200 nM SNX2112 (right panel) for 24,
48, and 72 hours. Clients examined demonstrate sensitivity to lower or higher concentrations with enhanced p53 and target p21
expression similar to those observed for UMSCC-1.
Figure W5. Effect of long-term SNX5422 treatment on tumor growth of UMSCC-1 in vivo. Placebo-controlled study of treatment with
20 mg/kg prodrug SNX5422 for 6.5 weeks revealed inhibition of tumor growth and an overall survival benefit. Comparison of (A) tumor
growth, (B) survival curves, and (C) body weight between control and treated animals. *P < .05 indicates statistical difference between
control and 20 mg/kg treated group (Student’s t test).
